Jazz Pharmaceuticals

News

Jazz breaks ground on $100m UK plant for cannabinoid drugs

Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture cannabinoid drugs from its recently

News

Wales is first UK country to fund GW's Epidyolex for tuberou...

Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by

News

Trial of Jazz' cannabis drug in glioblastoma will start next...

An investigator-led trial of Jazz Pharma's cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer - will get underway in the UK next year.

News

Jazz lifted by third EU approval for GW Pharma's Epidyolex

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion

News

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW P...

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex.

News

Harmony's sleep disorder drug Wakix gets US label extension

Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom of the sleep disorder that can cause total body collapse.

Jazz breaks ground on $100m UK plant for cannabinoid drugs

Wales is first UK country to fund GW's Epidyolex for tuberou...

Trial of Jazz' cannabis drug in glioblastoma will start next...

Jazz lifted by third EU approval for GW Pharma's Epidyolex

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW P...

Harmony's sleep disorder drug Wakix gets US label extension

Pay offer rejected as ICR researchers continue strike action

Discover a new era of healthcare panel engagement: Grounded ...

Jazz Pharmaceuticals

Editor's Picks